Batavia takeover allows CJ Cheiljedang to pursue two-track growth plan Deal follows Korean food and biotech company’s acquisition of ChunLab
Translated by Ryu Ho-joung 공개 2021-11-10 08:11:49
이 기사는 2021년 11월 10일 08:09 thebell 에 표출된 기사입니다.
CJ Cheiljedang, part of South Korea’s conglomerate CJ Group, is set to acquire Netherlands-based Batavia Biosciences only a few months after its acquisition of ChunLab – a move that will allow the food and biotech company to pursue a two-track strategy for future growth.CJ Cheiljedang has agreed to acquire a 76% stake in Batavia for about 195 million euros ($226 million), according to a regulatory filing on Monday.
Batavia, founded by pharmaceutical company Janssen's vaccine experts in 2010, specializes in developing manufacturing processes for viral vaccine and vector production. Post the acquisition, the current largest shareholder will remain the company’s second largest shareholder and continue to run the business.
The deal comes after CJ Cheiljedang acquired ChunLab, a Seoul-based bioinformatics company, this summer to create synergies in the microbiome field.
With its acquisition of Batavia, CJ Cheiljedang is stepping into the biopharmaceutical contract development and management organization (CDMO) market, expanding its business portfolio in the “red biotech” space – a term indicating biotechnology in the medical and pharmaceutical industries that involves biological compounds such as vaccines and antibiotics.
The CDMO business generates a steady revenue stream, which would help to reduce earnings volatility and also could be used to fund the development of new drugs and therapies.
Batavia counts global pharmaceutical companies and institutions – such as Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations, and International AIDS Vaccine Initiative – among its customers. It recorded revenue of 30.9 billion won ($26.2 million) in 2020 and 24 billion won in 2019.
The deal will also allow CJ Cheiljedang to be well positioned to benefit from the rapid growth in the market for cell and gene therapies. The market is forecast to grow at an average rate of 25% per year by 2025, especially with the use of the technology in the anticancer drug sector.
Competition is getting fierce in the cell and gene therapy CDMO market, with large medical and pharmaceutical companies continuing to expand their production capabilities for cell and gene therapies through acquisitions.
Thermo Fisher Scientific acquired Patheon in August 2017, Brammer Bio in March 2019 and Henogen in January 2021. Catalent bought Cook Pharmica in September 2017, Paragon Bioservices in April 2019 and MaSTherCell in February 2020. Samsung Biologics, the number one pharmaceutical CDMO in the world, earlier this year announced plans to expand its business to include gene therapies.
“The biopharmaceutical CDMO business generates steady revenue,” an official at CJ Cheiljedang said. “But on top of that, the growth potential of the market for cell and gene therapies is very appealing and it is even more so given that there are no dominant players in the market yet.”
SK Pharmteco, a pharmaceutical CDMO wholly owned by SK Inc, also acquired France-based Yposkesi in March this year to expand into the cell and gene therapy sector. It recorded revenue of 700 billion won in 2020 and is preparing for an initial public offering in New York in 2023. (Reporting by Ah-kyoung Lee)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 경남제약 품는 휴마시스, 유통네트워크·진단키트 '시너지'
- [Company Watch]글로벌텍스프리, 프랑스 자회사 '적자 전환'
- [Red & Blue]'주목도 높아지는 폐배터리' 새빗켐, 침묵 깨고 반등
- [HLB '리보세라닙' 미국 진출기]시장 우려 불식 나선 진양곤, 갑자기 마련된 기자회견
- 효성화학 특수가스 사업부, '경영권 지분 매각'으로 선회
- 한양, 만기도래 회사채 '사모채'로 차환한다
- 동인기연, 'GS 출신' 30년 베테랑 전호철 상무 영입 '성장 방점'
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진